Recently added articles from Advances in Gastrointestinal Cancer:
Individualising treatment options for patients.(Editorial)
Mar 01, 2008; ... Combination chemotherapy with or without the use of new antibodies is considered an important treatment option for patients with metastatic disease. However, it is unclear whether all our patients derive the same benefit from these treatments. It is therefore important to identify ...
Prognostic and predictive molecular markers in colorectal cancer: inhibition of the epidermal growth factor receptor.
Mar 01, 2008; ... Introduction The rapidly developing area of molecular markers is of increasing interest to oncologists as the armamentarium of effective drugs is becoming broader every year. However, despite positive results in large Phase III clinical trials, there are always some patients who ...
Prognostic clinical factors in metastatic colorectal cancer.
Mar 01, 2008; ... Introduction Clinical trials, although in theory using similar patient selection criteria, often display surprising heterogeneity in response and survival rates. One likely cause of this phenomenon is differences in patient characteristics or prognostic factors. The joint ...
Treatment of PS 2 patients with metastatic colorectal cancer.(performance status )
Mar 01, 2008; ... Introduction Metastatic colorectal cancer is sensitive to chemotherapy. Combination chemotherapy including infusional 5-fluorouracil (5FU)/leucovorin with irinotecan (FOLFIRI) or with oxaliplatin (FOLFOX) is considered a reference first-line chemotherapy. The best sequence of ...
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
Mar 01, 2008; ... Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases Reddy SK, Morse MA, Hurwitz HI et al. J Am Coll Surg, 2008, 206, 96-106 Resection of ...
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Mar 01, 2008; ... Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy Lassmann S, Tang L, Capanu M et al. Gastroenterology, 2007, 133, 1831-1839 Colorectal cancer (CRC) is the second leading cause of ...
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
Mar 01, 2008; ... Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases Min BS, Kim NK, Ahn JB et al. Onkologie, 2007, 30, 637-643 The treatment of liver ...
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma: a randomized phase III trial.
Mar 01, 2008; ... Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma: a randomized phase III trial Di Bartolomeo M, Buzzoni R, Mariani L et al. Oncology, 2007, epub ahead of print Over ...
Elderly patients and chemotherapy.(Editorial)(Report)
Dec 01, 2007; ... Median age at diagnosis for patients with colorectal cancer (CRC) is around 70 years in Western Europe and over 20% of patients are at least 80 years old. Management of CRC has been extensively investigated for younger patients and until a few years ago elderly patients were under-treated ...
Which patients should receive geriatric assessment before chemotherapy?(Report)
Dec 01, 2007; ... Introduction As a consequence of population ageing and the increasing incidence of cancers in advancing age, more than half of cancers occur after the age of about 70 years. All of the medical care establishments dealing with patients older than 75 years are interested in the ...
Cetuximab in elderly patients.(Clinical report)
Dec 01, 2007; ... Introduction Since the demonstration that 5-fluorouracil (5FU)-based chemotherapy provides benefit in elderly patients suffering from metastatic colorectal cancer (MCRC), in the absence of severe comorbidities, as it does in younger patients, these regimens have been used ...
Irinotecan-containing therapy in elderly patients with metastatic colorectal cancer.(Clinical report)
Dec 01, 2007; ... Introduction Chemotherapy for metastatic colorectal cancer has undergone rapid developments in the last few years. The progress began when irinotecan and oxaliplatin became available. In first-line therapy, both agents improved response rates and progression-free survival when ...
14th European Cancer Conference (ECCO), 2007.(Conference Report)(Report)
Dec 01, 2007; ... Introduction The 14th European Cancer Conference (ECCO) was held in Barcelona, Spain from 23-27 September 2007. This report will focus on the most interesting or promising results related to the treatment of gastrointestinal cancer that were presented during the meeting. ...
Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study.(Clinical report)
Dec 01, 2007; ... Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study Vinogradova Y, Hippisley-Cox J, Coupland C and Logan RF Gastroenterology, 2007, 133, 393-402. ...
Docetaxel in advanced gastric and gastro-oesophageal cancer.(Report)
Dec 01, 2007; ... Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastro-esophageal cancer adenocarcinoma: the V-325 Study Group Ajani JA, Moiseyenko VM, Tjulandin S et al. Journal of Clinical ...
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.(Clinical report)
Dec 01, 2007; ... Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial Oettle H, Post S, Neuhaus P et al. JAMA, 2007, 297, 267-277 Exocrine pancreatic ...
Multimodality treatment of liver metastases of colorectal cancer.(Editorial)
Sep 01, 2007; ... Approximately 25% of colorectal cancer (CRC) patients present with overt metastases, and an additional 25-35% of patients will develop metastases during the course of their disease. It is significant that approximately 30% of patients with advanced CRC have liver-only metastases, while ...
Histological changes in the liver after chemotherapy.
Sep 01, 2007; ... Introduction There is now accumulating evidence showing that chemotherapy is associated with pathological changes of liver parenchyma [1]. Because there is increasingly extensive use of neoadjuvant chemotherapy in advanced colorectal carcinoma, these recent data come mainly from ...
Classification of colorectal liver metastases.
Sep 01, 2007; ... Introduction Colorectal cancer is the commonest gastrointestinal malignancy and the second commonest cause of cancer death in Western society [1]. The liver is usually the first site of metastatic disease and may be the only site in approximately 30% of patients with advanced ...
Long-term survival of a patient with primarily unresectable liver metastasis from rectal cancer after neoadjuvant chemotherapy.(Case Report)
Sep 01, 2007; ... Introduction Resectability is the decisive factor for long-term survival of metastatic colorectal cancer. Unfortunately, only approximately 10% of patients with colorectal liver metastases have resectable disease. In the past decade, there has been a paradigm shift in treatment ...